Equity research analysts tracking Diaceutics PLC (LON: DXRX) maintain positive consensus forecasts with a "Buy" rating, pointing to a twelve-month average price target hovering around 215.00 GBX. Individual institutional forecasts suggest significant projected upside from its current trading levels, driven by expanding adoption of its DXRX precision medicine data platform across global pharmaceutical enterprises.